MDX-210 Bispecific antibody data

The Princeton, N.J., company reported data on patients who had failed multiple regimens of chemotherapy or hormonal therapy. In the Phase I/II trial in 15 patients, 10 of whom had measurable tumors, one patient had a partial remission.

A second patient had a mixed response, with some metastatic tumor sites shrunk by up to 90 percent but no measurable effect on bulky tumor masses. ...